VERA THERAPEUTICS INC. - CLASS A COMMON STOCK

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

04 Nov 2023 10:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Scheduled to Present at November Investor Conferences

30 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

13 Oct 2023 10:22:48 By Nasdaq GlobeNewswire

Vera Therapeutics Scheduled to Present at September Investor Conferences

31 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

10 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

17 Jun 2023 10:10:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

15 Jun 2023 16:44:21 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

08 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)

07 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results

11 May 2023 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

04 May 2023 08:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

28 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

27 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

06 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

01 Feb 2023 21:51:59 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

01 Feb 2023 16:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

30 Jan 2023 06:00:00 By Nasdaq GlobeNewswire

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

25 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

03 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

20 Dec 2022 16:05:00 By Nasdaq GlobeNewswire